I understand. Hide this message.
I understand. Hide this message.
Growth hormone therapy should not be initiated in patients with acute critical illness due to complications following open heart or abdominal surgery, multiple accidental trauma or acute respiratory failure. Zorbtive® is contraindicated in patients with active neoplasia (either newly diagnosed or recurrent). Any anti-tumor therapy should be completed prior to starting therapy with Zorbtive®. Zorbtive® is contraindicated in patients with a known hypersensitivity to growth hormone. Zorbtive® can cause serious side effects including allergic reactions, acute pancreatitis, diabetes or blood sugar problems, high blood pressure in the brain (intracranial hypertension), muscle or joint pain, swelling or stiffness, and carpal tunnel syndrome. Zorbtive® may also cause nausea, vomiting, stomach pain/gas and reactions at the injection site.
Please see Zorbtive® Prescribing Information.
Zorbtive® is a registered trademark of Merck KGaA, Darmstadt, Germany or its affiliates.
